AbbVie

A Covid-19 threat to business acquisitions
A Covid-19 threat to business acquisitions
EP Vantage
COVID-19
M&A
AbbVie
Allergan
Arya Sciences
Immatics
AcelRx
Tetraphase
Gilead Sciences
Forty Seven
Thermo Fisher
Stryker
Wright Medical
Flag link:
AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML
AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML
Pharmaceutical Business Review
AbbVie
Venclexta
azacitidine
clinical trials
AML
Flag link:
Go or no go? Covid-19 upstages US regulatory decisions
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Flag link:
AbbVie gives up patent rights to HIV med Kaletra amid COVID-19 tests: report
AbbVie gives up patent rights to HIV med Kaletra amid COVID-19 tests: report
Fierce Pharma
AbbVie
HIV
Kaletra
patents
COVID-19
Flag link:
AbbVie, Roche's Venclexta nails confirmatory combo trial in AML after flopping earlier study
AbbVie, Roche's Venclexta nails confirmatory combo trial in AML after flopping earlier study
Fierce Pharma
AbbVie
Roche
Venclexta
AML
clinical trials
Flag link:
AbbVie will allow generic copies of its HIV pill in Israel after the government approved a license
AbbVie will allow generic copies of its HIV pill in Israel after the government approved a license
Stat
AbbVie
Kaletra
generics
Israel
COVID-19
Flag link:
New data from randomized trial dent HIV drug strategy against Covid-19
New data from randomized trial dent HIV drug strategy against Covid-19
Endpoints
Kaletra
AbbVie
COVID-19
clinical trials
Flag link:
AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger
AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger
BioSpace
AbbVie
Allergan
FTC
M&A
Flag link:
AbbVie, Allergan merger may face regulatory delay due to COVID-19: report
AbbVie, Allergan merger may face regulatory delay due to COVID-19: report
Fierce Pharma
AbbVie
Allergan
FTC
M&A
COVID-19
Flag link:
AbbVie to Test HIV Drug as a Potential Coronavirus Treatment
AbbVie to Test HIV Drug as a Potential Coronavirus Treatment
Motley Fool
AbbVie
Kaletra
COVID-19
coronaviruses
HIV
Flag link:
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Endpoints
Bristol-Myers Squibb
Celgene
M&A
clinical trials
Multiple Myeloma
Empliciti
AbbVie
Revlimid
Flag link:
European regulators expand use of AbbVie's two-month hep C regimen
European regulators expand use of AbbVie's two-month hep C regimen
Endpoints
AbbVie
Europe
hepatitis C
Maviret
Flag link:
AbbVie and Allergan finally set (rough) date for wedding as one parent agrees to the match
AbbVie and Allergan finally set (rough) date for wedding as one parent agrees to the match
Endpoints
AbbVie
Allergan
M&A
Flag link:
AbbVie, Roche's Venclexta endangers AML approval with flopped confirmatory trial
AbbVie, Roche's Venclexta endangers AML approval with flopped confirmatory trial
Fierce Pharma
AbbVie
Roche
Venclexta
AML
blood cancer
FDA
Flag link:
Biohaven scores CGRP OK for acute migraine — can the commercial team catch up with Allergan on its debut?
Biohaven scores CGRP OK for acute migraine — can the commercial team catch up with Allergan on its debut?
Endpoints
Biohaven
FDA
migraines
Nurtec
Allergan
AbbVie
Ubrelvy
Flag link:
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
BioSpace
earnings
Bristol-Myers Squibb
AbbVie
Novo Nordisk
Merck
GSK
Seattle Genetics
Flag link:
AbbVie touts Humira defense strategy abroad as a positive sign for forthcoming U.S. battle
AbbVie touts Humira defense strategy abroad as a positive sign for forthcoming U.S. battle
Fierce Pharma
AbbVie
Humira
generics
patents
Flag link:
AbbVie's plan to replace Humira is ahead of schedule
AbbVie's plan to replace Humira is ahead of schedule
BioPharma Dive
AbbVie
Humira
Skyrizi
immunology
Flag link:
AbbVie Tops Q4 Profit Forecast, Sees Solid 2020 as New Drugs Boost Sales
AbbVie Tops Q4 Profit Forecast, Sees Solid 2020 as New Drugs Boost Sales
TheStreet.com
AbbVie
earnings
Flag link:
AbbVie Reports Successful Trial Results for Arthritis Drug
AbbVie Reports Successful Trial Results for Arthritis Drug
Motley Fool
AbbVie
Rinvoq
Upadacitinib
psoriasis
clinical trials
Flag link:

Pages